Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

Item
http://www.wikidata.org/entity/Q27027620
Future perspectives in target-specific immunotherapies of myasthenia gravisDesensitization: Overcoming the Immunologic Barriers to TransplantationThe HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyAntitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in PlantsRituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.
P2860

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

Item
http://www.wikidata.org/entity/Q27027620
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@ast
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@en
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@nl
type
label
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@ast
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@en
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@nl
prefLabel
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@ast
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@en
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@nl
P1433
P1476
P2093
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P698
P921
P3181
P356
P1433
P1476
Obinutuzumab (GA101) for the t ...... gineered type II CD20 antibody
@en
P2093
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P698
P921